...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 and Enzalutamide 2b Trial

"The clinical study is expected to start in Q2 2021."

Do we know the duration of the Phase 2b randomized study?

 

Koo

Share
New Message
Please login to post a reply